MentionFox
Home › Who owns › Iovance Biotherapeutics, Inc.
Owners, funding and legal record

Who owns Iovance Biotherapeutics, Inc.? Owners, funding and legal record

Before you sign with, sell to or invest in Iovance Biotherapeutics, Inc.

MentionFox check on Iovance Biotherapeutics, Inc.: no red flags found in 9 sources (checked 15 November 2026). mentionfox.com/c/who-owns/iovance-biotherapeutics

Check Iovance Biotherapeutics, Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about Iovance Biotherapeutics, Inc.?

Iovance Biotherapeutics, Inc. is a publicly traded company (Nasdaq: IOVA). The most recent 5%+ ownership report names State Street holding 5.5% (Schedule 13G, filed 2026-08-07).

As of November 15, 2026, Iovance Biotherapeutics, Inc. is a publicly traded company (Nasdaq: IOVA); its largest reported holder is BlackRock, with 7.5% on Schedule 13G/A of July 28, 2026. The largest insider holding is Frederick G. Vogt, the chief executive and general counsel, with 604,144 shares (0.13% of shares outstanding), per Form 4 of November 13, 2026 (Schedule 13G/A, July 28, 2026).

STATE STREET CORPORATION also filed stake reports on 378 other companies ↓

Is this your company?

About to sign with, pay or invest in Iovance Biotherapeutics, Inc.? See the free Snapshot first.

Watch Iovance Biotherapeutics, Inc.

Free to see. No signup.

Is Iovance Biotherapeutics, Inc. a real, registered company?

Before you sign or pay

Who are Iovance Biotherapeutics, Inc.'s owners and officers?

Iovance Biotherapeutics, Inc.: incorporated in Delaware; business address in San Carlos, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-10).

ReportHolderShare
Schedule 13G, 2026-11-10State Street Corporation4.8%
Schedule 13G, 2026-08-07State Street Corporation5.5%
Schedule 13G/A, 2026-07-28Blackrock, Inc.7.5%
Schedule 13G, 2026-05-12State Street Corporation4.2%
Schedule 13G/A, 2026-03-27The Vanguard Group0%
Schedule 13G, 2026-02-09State Street Corporation5.1%
Schedule 13G/A, 2025-07-29The Vanguard Group7.5%
Schedule 13G/A, 2025-07-17Blackrock, Inc.6.4%

Questions about who owns Iovance Biotherapeutics, Inc.

Who owns Iovance Biotherapeutics, Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Iovance Biotherapeutics, Inc.: Blackrock, Inc. (7.5%, Schedule 13G/A, filed 2026-07-28).

When did Blackrock, Inc. buy into Iovance Biotherapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2025-07-17, reporting 6.4%; its latest, Schedule 13G/A filed 2026-07-28, reports 7.5%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Want the whole picture on Iovance Biotherapeutics, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Iovance Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Iovance Biotherapeutics, Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    15 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.
FiledPersonRoleChangeEffective
Form 8-K, 2026-03-20Wendy YarnoDirectordeparted

Which insiders own Iovance Biotherapeutics, Inc. shares?

Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.

Shares outstanding: 462,655,151 as of 2026-10-27, from the company's latest SEC cover page.

How much has Iovance Biotherapeutics, Inc. raised?

No fundraising or offering filing from Iovance Biotherapeutics, Inc. is on file with us.

Keep reading

More on Iovance Biotherapeutics, Inc. and the records around it.

Companies that share a holder

Related pages

Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.

Not for employment, credit, insurance or tenancy decisions.

Cite this page

Permanent URL: https://mentionfox.com/who-owns/iovance-biotherapeutics
Last updated 2026-11-15
Who owns Iovance Biotherapeutics, Inc.? Owners, funding and legal record. MentionFox, 2026-11-15. https://mentionfox.com/who-owns/iovance-biotherapeutics